A Randomized, Open-Label, Phase III Trial of Afatinib (A) Vs Erlotinib (E) As Second-Line Treatment of Patients (Pts) with Advanced Squamous Cell Carcinoma (Scc) of the Lung Following First-Line Platinum-Based Chemotherapy: Lux-Lung 8 (Ll8)

Category Primary study
JournalAnnals of Oncology
Year 2014
This article has no abstract
Epistemonikos ID: fb3222739d6dd959e7e9d1b97a30c4a1a10542d2
First added on: Feb 19, 2025